Company Performance Metrics
- Robert Bitterman: President and Chief Executive Officer
Cutanea Life Sciences, Inc., a development stage specialty pharmaceutical company, focuses on in-licensing and developing therapeutics for the treatment of dermatological conditions. The company’s lead product candidate is omiganan (CLS001) for which it is preparing to initiate a Phase III clinical study for the treatment of rosacea, as well as
plans to initiate a Phase II clinical study for the treatment of atopic dermatitis. It also licensed the global rights for Chitosan (CLS002), an implantable bioresorbable gel based on chitin and chitosan to treat soft tissue abnormalities of the skin; and the dermatological North American rights to Ionic Contra Viral Therapy (ICVT) (CLS003), a topical antiviral product to treat non-genital warts caused by human papillomovirus. The company was formerly known as Pyxis Pharmaceuticals Inc. and changed its name to Cutanea Life Sciences, Inc. in March 2006. Cutanea Life Sciences, Inc. was founded in 2005 and is based in Wayne, Pennsylvania. As of February 13, 2012, Cutanea Life Sciences, Inc. operates as a subsidiary of Maruho Co., Ltd.
